<?xml version="1.0" encoding="UTF-8"?>
<p>When a pharmaceutical sponsor begins drug development and investigates an active substance for therapeutic potential there are many technical requirements necessary to obtain United States Food and Drug Administration (USFDA) approval pertaining to chemistry, manufacturing and controls, target animal safety, human food safety (if applicable), environmental impact, effectiveness and labelling [
 <xref rid="B64-animals-11-00892" ref-type="bibr">64</xref>]. In the US, certain cannabis-derived substances or their synthetic analogues have been approved for use in humans. These include the most recent approval of cannabis-derived CBD, Epidiolex [
 <xref rid="B65-animals-11-00892" ref-type="bibr">65</xref>] for the treatment of refractory epilepsy in children. Two synthetic formulations of THC have also been approved: Nabilone, brand name Cesamet [
 <xref rid="B66-animals-11-00892" ref-type="bibr">66</xref>], which was approved for use as an antiemetic in patients undergoing chemotherapy; and Marinol (Dronabinol) [
 <xref rid="B67-animals-11-00892" ref-type="bibr">67</xref>], which was approved for use as an appetite stimulant in patients with AIDS or cancer, but also used under “extra-label” guidelines as an analgesic.
</p>
